-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A team of researchers at UTHealth Houston said a newly developed agonist antibody could reduce amyloid pathology in mice with Alzheimer's disease, suggesting that it holds promise as a potential treatment for
The study, led by Professors Zhiqiang An and Robert Welch, found that a four-variable domain antibody against a trigger receptor expressed on myeloid 2 (TREM2) called TREM2 tmd-lg) reduced amyloid burden, reduced neuronal damage, and alleviated cognitive decline in
"Antibody-based therapy is a viable drug model for treating Alzheimer's disease," said An, who is director of
TREM2 is a single-pathway receptor
While previous studies have shown that TREM2 plays an important role in the pathophysiology of Alzheimer's disease, recent findings suggest that increasing the activation of TREM2 may have therapeutic effects
"By leveraging UTHealth Houston's unique antibody drug discovery capabilities and collaborating with scientists with complementary expertise, we demonstrate the feasibility of engineered polyvalent TREM2 agonist antibodies combined with TFR-mediated brain delivery to enhance microglia function and reduce amyloid pathology in vitro and in vivo," said
essay
Quadrivalent TREM2 agonist antibodies reduce amyloid pathology in mouse models of Alzheimer's disease
